证券代码：300078 证券简称：思创医惠 思创医惠科技股份有限公司 投资者关系活动记录表 编号：2017-0604 | --- | --- | --- | |-------------------------|------------------------|------------------------------------------------------| | | | | | | √ | 特定对象调研 □分析师会议 | | | □ | 媒体采访 □业绩说明会 | | 投资者关系活动 | □ | 新闻发布会 □路演活动 | | 类别 | □ 现场参观 | | | | | □其他 （请文字说明其他活动内容） | | | | 中信证券：刘雯蜀；平安证券：闫 磊；华证证券：庞倩倩 | | 参与单位名称及 人员姓名 | | 招商证券：刘玉萍；光大证券：卫书根；兴全基金：陆士杰 | | | | 大成基金：黄 政；上海世诚投资：沙小川 | | 时间 | 2017 年 6 月 7 | 日 | | 地点 | 杭州市滨江区东信大道 | 66 号东方通信城 D 座 | | 上市公司接待人 | 董秘兼财务总监 孙新军 ...

证券代码：300078 证券简称：思创医惠 思创医惠科技股份有限公司 投资者关系活动记录表 编号：2017-0202 | --- | --- | --- | |----------------|------------------------------|--------------------------------------------------------| | | | | | | √ | 特定对象调研 □分析师会议 | | | □ | 媒体采访 □业绩说明会 | | 投资者关系活动 | □ 新闻发布会 □路演活动 | | | 类别 | □ 现场参观 | | | | | □其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 中金公司：张景松、张义斌；平安证券：张峥青；招商证券： | | 人员姓名 | 资产：陶静。 | 刘玉萍；博时基金：李什；淡水泉投资：魏宇、张瀚宇；合从 | | 时间 | 2017 年 2 月 15 | 日 | | 地点 | 杭州市莫干山路 | 1418-48 号（上城科技经济园） | | 上市公司接待人 | 财务总监兼董秘 周为利 | | | 员姓名 | | | | ...

证券代码：300078 证券简称：思创医惠 思创医惠科技股份有限公司 投资者关系活动记录表 编号：2017-0101 | --- | --- | --- | |----------------|------------|--------------------------------------------------------| | | | | | | √ | 特定对象调研 □分析师会议 | | | □ | 媒体采访 □业绩说明会 | | 投资者关系活动 | □ | 新闻发布会 □路演活动 | | 类别 | □ 现场参观 | | | | | □其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 光大证券：姜国平、卫书根；中信建投证券：程杲；中信证 | | 人员姓名 | | 券：刘雯蜀、金田；海通证券：谢春生、黄竞晶、鲁力；华金 | | | | 证券：李东祥、方伟；平安证券：张峥青；方正证券：刘发 | | | | 扬、张建民；中金公司：张景松；东北证券：何柄谕；申银万 | | | | 国证券：刘高畅；民生证券：徐紫薇；渤海证券：王洪磊； | | | | 中银国际证券：宋彬；华泰证券：郭雅丽；国 ...

证券代码：300078 证券简称：思创医惠 思创医惠科技股份有限公司 投资者关系活动记录表 编号：2017-0906 | --- | --- | --- | |----------------|-----------------------------|------------------------------------------------------------| | | | | | | √ | 特定对象调研 □分析师会议 | | | □ | 媒体采访 □业绩说明会 | | 投资者关系活动 | □ 新闻发布会 □路演活动 | | | 类别 | □ 现场参观 | | | | | □其他 （请文字说明其他活动内容） | | | | 国泰君安证券：徐紫薇；银河证券：钱劲宇；信达证券：边铁 | | | 成； | | | | | 平安证券：闫磊 陈苏 张冰；上海铭环资产：聂天 樊一乐； | | 参与单位名称及 | | 上海证券：楼文才 张展伟 叶海 周嗣懿 焦思远 刘振伟 傅培军； | | 人员姓名 | | 葳尔资本：邵长清；杭州睿光投资：赵永志；吉祥人寿：巩伟； | | | | 中天国富证券：王耀祖；上海宝 ...

证券代码：300078 证券简称：思创医惠 思创医惠科技股份有限公司 投资者关系活动记录表 编号：2020-001 | --- | --- | --- | --- | |----------------|----------------------------------|------------------------------------------------------|----------| | | | | | | 投资者关系活动 | ☑ 特定对象调研 | □分析师会议 | | | 类别 | | □媒体采访 □业绩说明会 | | | | □新闻发布会 □路演活动 | | | | | □现场参观 | | | | | □其他 | | | | 参与单位名称及 | 太平洋证券 | 王文龙、安信证券 凌 晨、申万证券 | 洪依真、 | | 人员姓名 | 国盛证券 安 | 鹏、海通证券 杨 林、兴业证券 | 徐 聪、 | | | 新时代证券 | 田杰华、国信证券 于威业、光大证券 | 姜国平、 | | | 招商证券 | 范昳蕊、国泰君安 徐紫薇、中信证券 | 杨泽原、 | | | | | | | | 银河证券 ...

证券代码：300078 证券简称：思创医惠 思创医惠科技股份有限公司 投资者关系活动记录表 编号：2017-1207 | --- | --- | --- | |-----------------------|------------------------------|----------------------------------------------------| | | | | | | √ | 特定对象调研 □分析师会议 | | | □ | 媒体采访 □业绩说明会 | | 投资者关系活动 | □ | 新闻发布会 □路演活动 | | 类别 | □ 现场参观 | | | | | □其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 西部证券：梅迎娅；交银施罗德基金：王青雷； | | 人员姓名 | | 圆信永丰基金：浦宇佳；达晨创投：周光涛 | | 时间 | 2017 年 12 月 | 27 日 | | 地点 | 杭州市滨江区东信大道 | 66 号东方通信城 D 座 | | | 董事长、总经理 章笠中 | | | 上市公司接待人 员姓名 | 董事、副总经理兼董秘 孙新军 | | | | 证 ...

证券代码：300078 证券简称：思创医惠 思创医惠科技股份有限公司 投资者关系活动记录表 编号：2021-001 | --- | --- | --- | |----------------|------------|----------------------------------------------------| | | | | | | | 特定对象调研 □分析师会议 | | | □ | 媒体采访 □业绩说明会 | | 投资者关系活动 | □ | 新闻发布会 □路演活动 | | 类别 | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 浙商证券 田杰华、浙商证券 胥 辛、天风证券 刘 雄、 | | 人员姓名 | | 中泰证券 何柄谕、东北证券 邵珠印、华商基金 王 华、 | | | | 华宝基金 是星涛、兴全基金 陆士杰、景顺长城 江 磊、 | | | | 信达澳银 徐 聪、宝盈基金 朱建明、睿远基金 马 川、 | | | | 南方基金 史 博、南方基金 安永平、南方基金 陆宇轩、 | | | | 南方基金 卢玉珊、南方基金 李振兴、南方基金 ...

证券代码：300078 证券简称：思创医惠 思创医惠科技股份有限公司 投资者关系活动记录表 编号：2021-002 | --- | --- | --- | |-------------------------|-----------------------------------------|-------------------------------------------------------------------------------------------------------| | | □特定对象调研 | □分析师会议 | | | □媒体采访 □ | √ 业绩说明会 | | 投资者关系活动 | □新闻发布会 □路演活动 | | | 类别 | □现场参观 | | | | □其他 | （请文字说明其他活动内容） | | | | | | 参与单位名称及 人员姓名 | 参与思创医惠 2020 | 年度网上业绩说明会的投资者 | | 时间 | 2021 年 5 月 25 日 | 15:00 – 17:00 | | 地点 | 杭州市滨江区东方通信园 | D 座"医惠科技" | | | 董事长、总经理： ...

思创医惠科技股份有限公司 2022 年第三季度报告 | 证券代码：300078 | 证券简称：思创医惠 | 公告编号：2022-102 | | --- | --- | --- | | 债券代码：123096 | 债券简称：思创转债 | | 思创医惠科技股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第三季度报告是否经过审计 □是 否 1 思创医惠科技股份有限公司 2022 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末比上 | | --- | --- | --- | --- | --- | | ...

Financial Performance - The company's operating revenue for the first half of 2022 was ¥702,635,423.17, representing an increase of 8.11% compared to ¥649,918,633.92 in the same period last year[21]. - The net profit attributable to shareholders of the listed company decreased by 81.48% to ¥5,077,061.65 from ¥27,410,053.87 year-on-year[21]. - The net cash flow from operating activities was negative at ¥-174,169,793.61, a decline of 297.98% compared to ¥87,971,889.15 in the previous year[21]. - The basic earnings per share dropped by 66.67% to ¥0.01 from ¥0.03 in the same period last year[21]. - The gross profit margin for the total revenue was 35.83%, a decrease of 2.31% compared to the previous year[48]. - The company reported a significant increase in accounts receivable, which rose to ¥1,125,846,505.98, accounting for 23.23% of total assets, up from 18.06% the previous year[50]. - The company reported a net loss of ¥60,740,894.67 for the first half of 2022, an improvement from a loss of ¥65,817,956.32 in the previous period[170]. - The company reported a total revenue of 1.363 billion, a 5.0% increase compared to the previous year[191]. - The net profit attributable to shareholders was 729 million, reflecting a growth of 6.7% year-over-year[191]. Cash Flow and Investments - The net cash flow from investing activities improved by 157.50% to ¥283,372,093.08, mainly due to the maturity of bank wealth management products[46]. - The total cash inflow from financing activities was 458,500,000.00 CNY in the first half of 2022, down from 1,318,590,000.00 CNY in the same period of 2021, representing a decrease of approximately 65%[184]. - The net cash flow from financing activities was -26,146,489.42 CNY in the first half of 2022, compared to a positive net flow of 605,093,922.17 CNY in the first half of 2021[184]. - The company has invested a total of 47 million CNY in entrusted financial management, with an occurrence amount of 8.5 million CNY during the reporting period[66]. - The company reported a significant increase in cash received from other investment activities, totaling 1,222,930,100.00 CNY in the first half of 2022, compared to 311,693,962.90 CNY in the same period of 2021[184]. Assets and Liabilities - Total assets at the end of the reporting period were ¥4,847,133,347.13, a slight decrease of 0.34% from ¥4,863,530,760.78 at the end of the previous year[21]. - The company's total liabilities decreased slightly to ¥2,646,333,001.84 from ¥2,658,926,675.27, a decrease of approximately 0.5%[170]. - The company's long-term borrowings decreased to ¥489,335,635.59 from ¥584,722,815.20, a reduction of about 16.3%[170]. - The company's current ratio is 1.76, a decrease of 2.76% compared to the previous year[164]. - The asset-liability ratio stands at 54.60%, showing a slight decrease of 0.07% from the previous year[164]. Research and Development - Research and development expenses decreased by 7.12% to ¥96,525,127.62[46]. - The company has allocated 1,800,000 for research and development of new technologies[190]. - Research and development expenses accounted for 6.1% of total revenue, reflecting the company's commitment to innovation[192]. - The company has established a strong R&D team with multiple patents and software copyrights, crucial for maintaining its competitive edge[73]. Market Strategy and Expansion - The company is focusing on expanding its market presence through new product launches and technological advancements[44]. - The company plans to expand its market presence and invest in new product development to drive future growth[189]. - The company is exploring potential mergers and acquisitions to enhance its competitive position in the market[189]. - The company plans to expand its market presence in Southeast Asia, targeting a 15% increase in market share by the end of 2023[192]. - The company aims to achieve a revenue target of 2.5 billion for the full year 2022, representing a growth of 20%[192]. Corporate Governance and Compliance - The company has completed the modification of its articles of association and related governance rules to enhance corporate governance and clarify responsibilities[130]. - The company has implemented strict procurement contracts and pricing reviews to ensure the fairness of transactions, alongside establishing a management guideline for related party transactions[106]. - The company has not reported any major changes in the feasibility of its investment projects[63]. - The company has not encountered any major changes in its operational contracts that would significantly impact its financial performance[126]. Social Responsibility and Community Engagement - The company actively participated in the construction of 13 designated hospitals and makeshift hospitals during the COVID-19 pandemic, showcasing its commitment to social responsibility[99]. - The company established a health museum to promote medical and health knowledge among the public, enhancing its community engagement[98]. Employee Development and Retention - The company emphasizes employee rights and development, providing training and support for skill enhancement[97]. - The company recognizes the risk of talent loss in the knowledge-intensive industry and is implementing measures to enhance employee retention[73]. - The company has strengthened its internal training mechanisms for core employees to enhance loyalty and professional skills, while also considering incentive measures to align personal and corporate interests[74]. Risks and Challenges - The company faces intensified market competition in the smart medical and commercial intelligence sectors, requiring enhanced technological and service differentiation[72]. - The company faces risks from international trade policies and exchange rate fluctuations, particularly due to a significant export proportion in its business intelligence segment[74]. - The company is experiencing slow accounts receivable recovery due to business expansion, which may impact cash flow and increase operational funding needs[75]. - The company acknowledges risks associated with long-term equity investments and other non-current financial assets, which could lead to significant losses if market conditions worsen[76].